Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063713 · ClinicalTrials.gov registry record · Phase 2
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
A Phase 2 study of Mantle Cell Lymphoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT00063713: Completed Phase 2 study of Mantle Cell Lymphoma, sponsored by Millennium Pharmaceuticals.
NCT00063713 is a Phase 2 study of Mantle Cell Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 152 participants, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00063713, a Phase 2 study of Mantle Cell Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
Conditions Studied
Interventions
- DRUG VELCADE TM (bortezomib) for Injection
Study Locations (20)
California
- Alta Bates Medical Center - Berkeley
- City of Hope Comprehensive Cancer Center - Duarte
- Loma Linda Cancer Research Institute - Loma Linda
- UCLA School of Medicine - Los Angeles
- Stanford University - Palo Alto
Illinois
- The Rush Cancer Center - Chicago
- University of Chicago Medical Center - Chicago
New York
- Beth Israel Medical Center - New York
- St Lukes-Roosevelt Hospital - New York
Alabama
- University of Alabama - Birmingham
Colorado
- University of Colorado Cancer - Denver
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Georgia
- The Emory Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2003-06 |
| Phase | Phase 2 |
What the finished NCT00063713 record still lists
NCT00063713 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which VELCADE TM (bortezomib) for Injection is the first listed.
NCT00063713 names 20 study sites across 14 states, led by California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00063713 about?
NCT00063713 is a clinical study titled "VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma". The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
What is the current status of trial NCT00063713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2003-06.
What conditions does trial NCT00063713 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma.
What interventions are being tested in trial NCT00063713?
The interventions under investigation include: VELCADE TM (bortezomib) for Injection (DRUG).
Who is sponsoring clinical trial NCT00063713?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00063713 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00063713's enrollment target sits among peer trials
152 18th of 102 higher than 85 of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
RECRUITING · Phase 2
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia